Type 1 Diabetes (Juvenile Diabetes) 2018 Pipeline Review, Therapeutic Development & Assessment, Key Players Inolved and Drug Profiles - ResearchAndMarkets.com

DUBLIN--()--The "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Type 1 Diabetes (Juvenile Diabetes) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type1 diabetes (Juvenile Diabetes) and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 11, 33, 29, 2, 102, 32 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 2, 30 and 4 molecules, respectively.

Companies Mentioned

  • Adocia SAS
  • AiCuris GmbH & Co KG
  • Allist Shanghai Pharmaceutical Technology Co Ltd
  • Amarantus Bioscience Holdings Inc
  • Amarna Therapeutics BV
  • apceth Biopharma GmbH
  • Aphios Corp
  • Apodemus AB
  • Arecor Ltd
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Atlantic Bio Sci LLC
  • Axxam SpA
  • Beta-Cell NV
  • Biocon Ltd
  • BioLineRx Ltd
  • BioLingus AG
  • Biozeus
  • BirchBioMed Inc
  • Boehringer Ingelheim GmbH
  • Boston Therapeutics Inc
  • BTB Pharma AB
  • Caladrius Biosciences Inc
  • Cancer Prevention Pharmaceuticals Inc
  • Cellix Bio Pvt Ltd
  • Compugen Ltd
  • Daewoong Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • Merck & Co Inc
  • Novo Nordisk AS
  • Pfizer Inc
  • Sanofi

Key Topics Covered

  1. Introduction
  2. Type1 diabetes (Juvenile Diabetes) - Overview
  3. Type1 diabetes (Juvenile Diabetes) - Therapeutics Development
  4. Type1 diabetes (Juvenile Diabetes) - Therapeutics Assessment
  5. Type1 diabetes (Juvenile Diabetes) - Companies Involved in Therapeutics Development
  6. Type1 diabetes (Juvenile Diabetes) - Drug Profiles
  7. Type1 diabetes (Juvenile Diabetes) - Dormant Projects
  8. Type1 diabetes (Juvenile Diabetes) - Discontinued Products
  9. Type1 diabetes (Juvenile Diabetes) - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/k5295z/type_1_diabetes?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Endocrine and Metabolic Disorders Drugs